Items in cart [1] Questions? Call 888-624-8373

Rights & Permissions Free PDF Access Free Resources Sign in to download PDF book and chapters Display this book on your site! Related Titles Cancer Biomarkers: The Promises and Challenges of Improving Detection and Treatment From Cancer Patient to Cancer Survivor: Lost in Transition Other Related Titles Federal Agency Roles in Cancer Drug Development from Preclinical Research to New Drug Approval: The National Cancer Institute and the Food and Drug Administration (2005) Web Search Builder Use this book's key terms to search within this book, across our collection, or across the Web. Skim This Chapter Skim this chapter and use this chapter's key terms to search within this book. Reference Finder Paste in your own text to find books that relate to your topic. Page 61   E-mail  Facebook  Digg  Stumble  Twitter More The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy. ACRONYMS AND ABBREVIATIONS BDP Biopharmaceutical Development Program BLA Biologics License Application BRM Biological Response Modifier CBER Center for Biologics Evaluation and Research CCNSC Cancer Chemotherapy National Service Center CDER Center for Drug Evaluation and Research CDRH Center for Devices and Radiological Health CFR U.S. Code of Federal Regulations CFSAN Center for Food Safety and Applied Nutrition CGAP Cancer Genome Anatomy Project CMS Centers for Medicare and Medicaid Services DCTD Division of Cancer Treatment and Diagnosis DNA Deoxyribonucleic acid DTP Developmental Therapeutics Program EDRN Early Detection Research Network ELA Establishment Licensing Application FDA Food and Drug Administration FDAMA Food and Drug Administration Modernization Act of 1997 FDCA Food, Drug, and Cosmetic Act of 1938 FLAIR Flexible System to Advance Innovative Research IND Investigational New Drug Exemption IRB Institutional Review Board LMT Laboratory of Molecular Technology NCAB National Cancer Advisory Board NCCN National Comprehensive Cancer Network NCDDG National Cooperative Drug Discovery Group Program NDA New Drug Application NIH National Institutes of Health NME New Molecular Entity ODAC Oncologic Drugs Advisory Board ODP Office of Oncology Drug Products OTC Over-the-Counter (non-prescription) drug PDUFA Prescription Drug User Fee Act of 1992 PhRMA Pharmaceutical Research and Manufacturers of America PLA Product License Application RAID Rapid Access to Intervention Development Program RAMEM Radiation Modifier Evaluation Module Program RAND Rapid Access to NCI Discovery Resources Program RFA Request for Applications RNA Ribonucleic Acid SAGE Serial Analysis of Gene Expression SPORE Specialized Program of Research Excellence TIP Time to progression Page 61 Front Matter (R1-R8) 1 Scientific Rationale (1-6) 2 The National Cancer Institute (7-27) 3 The Food and Drug Administration (28-53) 4 Summary: The Roles of the NCI and the FDA in Developing Anticancer Agents (54-55) References (56-60) Acronyms and Abbreviations (61-61)

Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 61
Federal Agency Roles in Cancer Drug Development from Preclinical Research to New Drug Approval: The National Cancer Institute and the Food and Drug Administration ACRONYMS AND ABBREVIATIONS BDP Biopharmaceutical Development Program BLA Biologics License Application BRM Biological Response Modifier CBER Center for Biologics Evaluation and Research CCNSC Cancer Chemotherapy National Service Center CDER Center for Drug Evaluation and Research CDRH Center for Devices and Radiological Health CFR U.S. Code of Federal Regulations CFSAN Center for Food Safety and Applied Nutrition CGAP Cancer Genome Anatomy Project CMS Centers for Medicare and Medicaid Services DCTD Division of Cancer Treatment and Diagnosis DNA Deoxyribonucleic acid DTP Developmental Therapeutics Program EDRN Early Detection Research Network ELA Establishment Licensing Application FDA Food and Drug Administration FDAMA Food and Drug Administration Modernization Act of 1997 FDCA Food, Drug, and Cosmetic Act of 1938 FLAIR Flexible System to Advance Innovative Research IND Investigational New Drug Exemption IRB Institutional Review Board LMT Laboratory of Molecular Technology NCAB National Cancer Advisory Board NCCN National Comprehensive Cancer Network NCDDG National Cooperative Drug Discovery Group Program NDA New Drug Application NIH National Institutes of Health NME New Molecular Entity ODAC Oncologic Drugs Advisory Board ODP Office of Oncology Drug Products OTC Over-the-Counter (non-prescription) drug PDUFA Prescription Drug User Fee Act of 1992 PhRMA Pharmaceutical Research and Manufacturers of America PLA Product License Application RAID Rapid Access to Intervention Development Program RAMEM Radiation Modifier Evaluation Module Program RAND Rapid Access to NCI Discovery Resources Program RFA Request for Applications RNA Ribonucleic Acid SAGE Serial Analysis of Gene Expression SPORE Specialized Program of Research Excellence TIP Time to progression

Representative terms from entire chapter:

dtp developmental